JP2019502902A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502902A5 JP2019502902A5 JP2018525768A JP2018525768A JP2019502902A5 JP 2019502902 A5 JP2019502902 A5 JP 2019502902A5 JP 2018525768 A JP2018525768 A JP 2018525768A JP 2018525768 A JP2018525768 A JP 2018525768A JP 2019502902 A5 JP2019502902 A5 JP 2019502902A5
- Authority
- JP
- Japan
- Prior art keywords
- pkd
- patient
- fluoro
- sample
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000030761 polycystic kidney disease Diseases 0.000 claims 33
- 238000000034 method Methods 0.000 claims 20
- 101000797623 Homo sapiens Protein AMBP Proteins 0.000 claims 19
- 102100032859 Protein AMBP Human genes 0.000 claims 19
- -1 4- (4-((2-methoxyethoxy) methyl) phenyl) pyrimidin-2-yl Chemical group 0.000 claims 15
- 210000001124 body fluid Anatomy 0.000 claims 6
- 239000010839 body fluid Substances 0.000 claims 6
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 claims 4
- 108091000114 ceramide glucosyltransferase Proteins 0.000 claims 4
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 4
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 3
- OJCLMSVFVVKWJX-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl n-[2-[3-(4-fluorophenyl)phenyl]propan-2-yl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC(C)(C)C(C=1)=CC=CC=1C1=CC=C(F)C=C1 OJCLMSVFVVKWJX-UHFFFAOYSA-N 0.000 claims 2
- KWLRZSSADMGVLE-UHFFFAOYSA-N 4-fluoro-1-[4-[4-(2-fluoroethoxy)phenyl]pyrimidin-2-yl]-n-(4-methyl-1-azabicyclo[3.2.2]nonan-4-yl)piperidine-4-carboxamide Chemical compound C1CN(CC2)CCC2C1(C)NC(=O)C(CC1)(F)CCN1C(N=1)=NC=CC=1C1=CC=C(OCCF)C=C1 KWLRZSSADMGVLE-UHFFFAOYSA-N 0.000 claims 2
- BHQKXEPIAXCKKU-UHFFFAOYSA-N 4-fluoro-1-[5-fluoro-4-[4-(2-methoxyethoxymethyl)phenyl]pyrimidin-2-yl]-n-(4-methyl-1-azabicyclo[3.2.2]nonan-4-yl)piperidine-4-carboxamide Chemical compound C1=CC(COCCOC)=CC=C1C1=NC(N2CCC(F)(CC2)C(=O)NC2(C)C3CCN(CC3)CC2)=NC=C1F BHQKXEPIAXCKKU-UHFFFAOYSA-N 0.000 claims 2
- UMWIMNNPYBWNRY-XMMPIXPASA-N [(3s)-1-azabicyclo[2.2.2]octan-3-yl] n-[2-[4-[4-(2-methoxyethoxy)phenyl]phenyl]propan-2-yl]carbamate Chemical compound C1=CC(OCCOC)=CC=C1C1=CC=C(C(C)(C)NC(=O)O[C@H]2C3CCN(CC3)C2)C=C1 UMWIMNNPYBWNRY-XMMPIXPASA-N 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 2
- 125000001207 fluorophenyl group Chemical group 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000005084 renal tissue Anatomy 0.000 claims 2
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical group C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 claims 2
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 2
- NMAHPRBPCRWREJ-UHFFFAOYSA-N 4-fluoro-1-[4-[4-(2-methoxyethoxy)phenyl]pyrimidin-2-yl]-N-(4-methyl-1-azabicyclo[3.2.2]nonan-4-yl)piperidine-4-carboxamide Chemical compound FC1(CCN(CC1)C1=NC=CC(=N1)C1=CC=C(C=C1)OCCOC)C(=O)NC1(CCN2CCC1CC2)C NMAHPRBPCRWREJ-UHFFFAOYSA-N 0.000 claims 1
- 229940125921 glucosylceramide synthase inhibitor Drugs 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257089P | 2015-11-18 | 2015-11-18 | |
| US62/257,089 | 2015-11-18 | ||
| PCT/US2016/062075 WO2017087409A1 (en) | 2015-11-18 | 2016-11-15 | Biomarker of polycystic kidney disease and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502902A JP2019502902A (ja) | 2019-01-31 |
| JP2019502902A5 true JP2019502902A5 (enExample) | 2019-12-26 |
| JP6895963B2 JP6895963B2 (ja) | 2021-06-30 |
Family
ID=57539614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525768A Active JP6895963B2 (ja) | 2015-11-18 | 2016-11-15 | 多発性嚢胞腎のバイオマーカーおよびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11116755B2 (enExample) |
| EP (1) | EP3377908B1 (enExample) |
| JP (1) | JP6895963B2 (enExample) |
| KR (1) | KR20180083902A (enExample) |
| CN (1) | CN108700594B (enExample) |
| AU (1) | AU2016357720A1 (enExample) |
| BR (1) | BR112018009879A2 (enExample) |
| CO (1) | CO2018006126A2 (enExample) |
| EA (1) | EA201891170A1 (enExample) |
| MX (1) | MX2018006250A (enExample) |
| WO (1) | WO2017087409A1 (enExample) |
| ZA (1) | ZA201803035B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11116755B2 (en) | 2015-11-18 | 2021-09-14 | Genzyme Corporation | Biomarker of polycystic kidney disease and uses thereof |
| PL3920912T3 (pl) * | 2019-02-04 | 2025-11-12 | Genzyme Corporation | Leczenie ciliopatii przy użyciu inhibitorów syntazy glukozyloceramidowej (gcs) |
| KR102859441B1 (ko) * | 2019-11-22 | 2025-09-12 | 서울대학교산학협력단 | Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용 |
| JPWO2023145898A1 (enExample) * | 2022-01-27 | 2023-08-03 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710227B1 (en) | 1998-09-16 | 2004-03-23 | Cropdesign N.V. | Cyclin-dependent kinase inhibitors and uses thereof |
| US6703395B2 (en) | 1998-03-04 | 2004-03-09 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | Cyclin dependent kinase inhibitor |
| US20040006074A1 (en) | 1998-04-28 | 2004-01-08 | The Government Of The United States Of America | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer |
| CA2256121A1 (en) | 1998-06-08 | 1999-12-08 | Hong Wang | Cyclin-dependent kinase inhibitors as plant growth regulators |
| ATE318818T1 (de) | 1998-06-16 | 2006-03-15 | Us Gov Health & Human Serv | Annellierte azepinone als inhibitoren cyclin- abhängiger kinasen |
| US6559152B2 (en) | 1998-10-13 | 2003-05-06 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| JP2003500418A (ja) | 1999-05-24 | 2003-01-07 | エイブイアイ バイオファーマ， インコーポレイテッド | 多発性嚢胞腎疾患の処置のためのｃ−ｍｙｃに対するアンチセンス |
| US6593356B2 (en) | 1999-10-20 | 2003-07-15 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| US20040048844A1 (en) | 1999-10-20 | 2004-03-11 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| WO2001081348A1 (en) | 2000-04-25 | 2001-11-01 | Bristol-Myers Squibb Company | USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO[3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| US20050004007A1 (en) | 2000-09-12 | 2005-01-06 | Steven Grant | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
| AU2509602A (en) | 2000-12-20 | 2002-07-01 | Sod Conseils Rech Applic | Cyclin-dependent kinase (CDK) and glycolene synthase kinase-3 (GSK-3) inhibitors |
| GB0101686D0 (en) | 2001-01-23 | 2001-03-07 | Cancer Res Campaign Tech | Cyclin dependent kinase inhibitors |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| WO2003063764A2 (en) | 2001-07-10 | 2003-08-07 | Bristol-Myers Squibb Pharma Company | 6-SUBSTITUTED PYRAZOLO [3,4-d] PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| MXPA05002573A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| MXPA05002572A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Compuestos pirazolo[1,5-a]pirimidinas como inhibidores de cinasa depentes de ciclina. |
| NZ539164A (en) | 2002-09-04 | 2006-04-28 | Schering Corp | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CN1694705A (zh) | 2002-09-04 | 2005-11-09 | 先灵公司 | 用作依赖细胞周期蛋白激酶抑制剂的吡唑并嘧啶 |
| US7196092B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CA2499639C (en) | 2002-09-19 | 2011-11-08 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
| CA2499593C (en) | 2002-09-19 | 2011-08-16 | Michael P. Dwyer | Pyrazolopyridines as cyclin dependent kinase inhibitors |
| JP2006503838A (ja) | 2002-09-23 | 2006-02-02 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしての新規イミダゾピラジン |
| ATE377600T1 (de) | 2002-09-23 | 2007-11-15 | Schering Corp | Imidazopyrazine als cdk-inhibitoren |
| US7576085B2 (en) | 2002-09-23 | 2009-08-18 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| GB0313677D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
| US9006181B2 (en) | 2004-07-21 | 2015-04-14 | The Administrators Of The Tulane Educational Fund | Treatment of renal dysfunction and multiple myeloma using PACAP compounds |
| EP1808694A1 (en) | 2006-01-17 | 2007-07-18 | Universitätsklinikum Freiburg | Method for diagnosing polycystic kidney disease |
| EP2594562B1 (en) | 2007-05-31 | 2016-07-20 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| JP5661457B2 (ja) | 2007-06-06 | 2015-01-28 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． | 腎疾患の予測診断 |
| US8389517B2 (en) | 2008-07-28 | 2013-03-05 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| CN107935983A (zh) | 2008-10-03 | 2018-04-20 | 简詹姆公司 | 2‑酰胺基丙醇型葡糖神经酰胺合酶抑制剂 |
| US20120077263A1 (en) | 2009-06-05 | 2012-03-29 | Mayo Foundation For Medical Education And Research | Methods and materials for isolating exosomes |
| CN102858985A (zh) * | 2009-07-24 | 2013-01-02 | 西格马-奥尔德里奇有限责任公司 | 基因组编辑方法 |
| CN102018702B (zh) | 2009-09-16 | 2012-07-18 | 北京大学 | 银杏内酯b的一种用途 |
| NZ625712A (en) | 2009-11-27 | 2016-02-26 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| US20110195903A1 (en) | 2009-12-15 | 2011-08-11 | Adra Chaker N | Methods and compositions for detecting recessive familial fsgs and uses thereof |
| US20140079769A1 (en) | 2010-10-01 | 2014-03-20 | Fabiola Terzi | Methods for predicting the progression and treating a chronic kidney disease in a patient |
| US20130276513A1 (en) * | 2010-10-14 | 2013-10-24 | The Regents Of The University Of California | Methods for diagnosing and assessing kidney disease |
| JP6021021B2 (ja) | 2010-11-05 | 2016-11-02 | 国立大学法人京都大学 | 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法 |
| SG11201401222WA (en) | 2011-10-03 | 2014-09-26 | Celmatix Inc | Methods and devices for assessing risk to a putative offspring of developing a condition |
| WO2013059119A1 (en) | 2011-10-17 | 2013-04-25 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| CN102590491B (zh) | 2012-02-06 | 2014-12-10 | 中国人民解放军第三军医大学第一附属医院 | 一种用于早期筛查或辅助诊断泌尿系统疾病的检测试剂盒、检测方法及其用途 |
| ES2982997T3 (es) | 2012-07-03 | 2024-10-21 | Fond Centro San Raffaele | 2-desoxiglucosa para uso en el tratamiento de la enfermedad renal poliquística dominante autosomal o enfermedad hepática poliquística |
| JOP20130273B1 (ar) * | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| JP6730252B2 (ja) | 2014-08-04 | 2020-07-29 | ジェンザイム・コーポレーション | 多発性嚢胞腎のバイオマーカーおよびその使用 |
| US11116755B2 (en) | 2015-11-18 | 2021-09-14 | Genzyme Corporation | Biomarker of polycystic kidney disease and uses thereof |
-
2016
- 2016-11-15 US US15/775,736 patent/US11116755B2/en active Active
- 2016-11-15 CN CN201680079045.XA patent/CN108700594B/zh active Active
- 2016-11-15 EA EA201891170A patent/EA201891170A1/ru unknown
- 2016-11-15 WO PCT/US2016/062075 patent/WO2017087409A1/en not_active Ceased
- 2016-11-15 JP JP2018525768A patent/JP6895963B2/ja active Active
- 2016-11-15 MX MX2018006250A patent/MX2018006250A/es unknown
- 2016-11-15 BR BR112018009879A patent/BR112018009879A2/pt not_active Application Discontinuation
- 2016-11-15 EP EP16809582.6A patent/EP3377908B1/en active Active
- 2016-11-15 AU AU2016357720A patent/AU2016357720A1/en not_active Abandoned
- 2016-11-15 KR KR1020187016766A patent/KR20180083902A/ko not_active Withdrawn
-
2018
- 2018-05-09 ZA ZA2018/03035A patent/ZA201803035B/en unknown
- 2018-06-15 CO CONC2018/0006126A patent/CO2018006126A2/es unknown
-
2021
- 2021-08-17 US US17/404,701 patent/US12150938B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519763A5 (enExample) | ||
| JP2019502902A5 (enExample) | ||
| Shah et al. | An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer | |
| RU2015144149A (ru) | Протеомные маркеры илф | |
| US12150938B2 (en) | Biomarker of polycystic kidney disease and uses thereof | |
| Xie et al. | Acute hyperglycemia suppresses left ventricular diastolic function and inhibits autophagic flux in mice under prohypertrophic stimulation | |
| Bengtson et al. | An open label trial to assess safety of losartan for treating worsening respiratory illness in COVID-19 | |
| Wong et al. | Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model | |
| US8288087B2 (en) | Use of melanoma inhibitory activity (MIA) protein as an early indicator for therapeutic response in melanoma | |
| Yoshida et al. | Metformin prevents the development of monocrotaline-induced pulmonary hypertension by decreasing serum levels of big endothelin-1 | |
| JP7005695B2 (ja) | 多発性嚢胞腎のバイオマーカーおよびその使用 | |
| Xue et al. | Superiority of Low‐Dose Benzbromarone Add‐On to Low‐Dose Febuxostat Compared With Febuxostat Monotherapy in Gout With Combined‐Type Hyperuricemia | |
| Zhao et al. | Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF‑κB signaling pathway | |
| JP2017525955A5 (enExample) | ||
| Saheb Sharif-Askari et al. | Calprotectin inhibition attenuates silica-induced lung fibrosis | |
| Nakajima et al. | Standard treatment in daily clinical practice for early rheumatoid arthritis improved disease activity from 2001 to 2006 | |
| Piccaluga et al. | Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia | |
| US20250170129A1 (en) | Senotherapeutic agents and alpha-klotho polypeptides | |
| Cho et al. | Clinical usefulness of transarterial chemoembolization response prior to liver transplantation as predictor of optimal timing for living donor liver transplantation | |
| Huston et al. | Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension | |
| Inoue et al. | INCIDENCE AND RISK FACTORS OF POSTOPERATIVE HYPERTENSION AFTER PARTIAL NEPHRECTOMY FOR RENAL TUMORS: MP49-07 | |
| Lubel | How to Deal with Patients with Active Hepatitis B & C | |
| Migliorati | key topics in supportive care |